Gapping up
In reaction to earnings/guidance:
- NEWR +3.8% (guidance), AAL +2% (guidance)
Other news:
- DICE +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
- ALBO +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevixibat) in Alagille Syndrome)
- SPNE +16.7% (Orthofix and SeaSpine (SPNE) to combine in merger of equals to create leading global spine and orthopedics company; issue guidance)
- JOBY +10.4% (Joby Aviation and Delta (DAL) partner to pioneer home-to-airport transportation)
- TRC +4.8% (appoints Drew Hammer as CFO)
- ANGI +4.4% (CEO steps down; appoints new CEO)
- BKD +1.5% (reports September 2022 occupancy)
- ANDE +1.3% (to purchase Mote Farm Service)
Analyst comments:
- WMG +2.9% (initiated with a Buy at Goldman)
- ABC +0.7% (upgraded to Buy from Neutral at BofA Securities)
